Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study

✍ Scribed by E. Briasoulis; G. Fountzilas; A. Bamias; M. A. Dimopoulos; N. Xiros; G. Aravantinos; E. Samantas; H. Kalofonos; T. Makatsoris; N. Mylonakis; P. Papakostas; D. Skarlos; I. Varthalitis; N. Pavlidis

• Publisher: Springer
• Year: 2007
• Tongue: English
• Weight: 329 KB
• Volume: 62
• Category: Article
• ISSN: 0344-5704
• DOI: 10.1007/s00280-007-0604-7